Securities Fraud Class Action Filed Against uniQure N.V. Following FDA Approval Delay and 49% Stock Decline

A recent Securities Fraud Class Action against uniQure N.V. has resulted in significant losses for investors due to a delay in FDA approval and subsequent stock decline. This has prompted a reminder from Kahn Swick & Foti, LLC about the upcoming deadline for investors to file applications as lead plaintiffs in the securities class action lawsuit against uniQure N.V. Those who purchased or acquired the Company’s shares between September 24, 2025, and October 31, 2025, have until April 13, 2026, to take action.

During the Class Period, uniQure reassured investors that their leading drug candidate, AMT-130, was likely to receive accelerated FDA approval after the planned Biologics License Application (BLA) submission in the first quarter of 2026. However, on November 3, 2025, the Company revealed that the FDA no longer agreed that the data from the Phase I/II studies of AMT-130 met the criteria for a BLA submission, leading to uncertainty regarding the timing of the submission. As a result of this announcement, uniQure’s stock price plummeted by over 49%, causing significant financial losses for investors who had purchased shares during the Class Period.

The case, known as Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, highlights the importance of transparency and compliance with federal securities laws. uniQure and certain executives are being accused of withholding material information from investors during the Class Period, a violation of securities regulations. Investors who suffered losses due to this alleged misconduct have the opportunity to seek restitution by participating in the class action lawsuit.

Kahn Swick & Foti, LLC, a leading securities litigation law firm, is actively working on behalf of investors to hold companies like uniQure accountable for corporate fraud or malfeasance. With a track record of successfully recovering losses for clients impacted by financial misconduct, KSF is dedicated to seeking justice for both institutional and retail investors affected by deceptive practices in the market.

Investors who believe they may have grounds to participate in the uniQure N.V. securities fraud class action are encouraged to contact KSF for a consultation on their legal rights and options. The deadline to file as a lead plaintiff in this case is April 13, 2026, and investors are advised to take prompt action to protect their interests. By staying informed and proactive, investors can help ensure accountability and integrity in the financial markets, promoting transparency and fairness for all stakeholders.